NCT06527495View on ClinicalTrials.gov

Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions

HCCHepatocellular Carcinoma

Interventions

DRUG

Sorafenib

Sorafenib Tablets (200 -400 mg) twice daily

Trial Locations (1)

32511

RECRUITING

NLI, Shibīn al Kawm

All Listed Sponsors

lead

Assiut University

OTHER